Industry veteran joins Auxilium Pharmaceuticals

Adrian Adams succeeds Armando Anido at the US firm

Auxilium Pharmaceuticals, a specialist biopharmaceutical company based in Malvern, PA, US, has appointed Adrian Adams as chief executive and president, effective immediately. Adams succeeds Armando Anido, who has agreed to step down and has resigned as a member of the Board. Adams will also succeed him on the Board.

Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as chairman and ceo of Neurologix, a biotechnology company engaged in the development of gene therapies for disorders of the brain and central nervous system. Prior to that, he was president and ceo of Inspire Pharmaceuticals, where he oversaw the development and commercialisation of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co.

Before joining Inspire, Adams was president and ceo of Sepracor until its acquisition by Dainippon Sumitomo Pharma Co in 2010. Prior to this, he was president and ceo of Kos Pharmaceuticals from 2002 until the company was acquired by Abbott Laboratories in 2006.

Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).

You may also like

Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Pharmaceutical

White paper: Leadership as the missing control in the Pharmaceutical Quality System (PQS)

Why senior management determines the effectiveness of the pharmaceutical quality system
Regulatory

Oncopeptides to seek EMA label expansion for Pepaxti to include third-line multiple myeloma treatment

The company has said it will submit a Type II variation to the EMA to expand Pepaxti's indication to include patients with multiple myeloma who have received at least two prior lines of therapy — a move that would double the addressable patient population and treatment cycle potential in Europe
Pharmaceutical

Ardena strengthens executive team to drive its next phase of growth

Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Subscribe now